@article{article_304373, title={Severe bone marrow suppression following single-dose methotrexate treatment for ectopic pregnancy}, journal={The European Research Journal}, volume={3}, pages={285–289}, year={2017}, DOI={10.18621/eurj.304373}, author={Dündar, Betül and Dinçgez Çakmak, Burcu and Özgen, Gülten and Ketenci Gencer, Fatma and Aydın Boyama, Burcu}, keywords={Bone marrow suppression,ectopic pregnancy,methotrexate,side effects,single-dose regimen}, abstract={<p class="MsoNormal" style="text-align:justify;line-height:200%;"> <span lang="en-us" style="font-size:12pt;line-height:200%;font-family:’Times New Roman’, serif;" xml:lang="en-us">Methotrexate is associated with multisystem side
effects which depend on the dosage, route of administration and length of
treatment. Bone marrow suppression is a very rare but one of the most mortal
complications. A case of severe bone marrow suppression following single dose
methotrexate for ectopic pregnancy was presented in this study. A 33-year-old woman,
diagnosed as ectopic pregnancy, was given single-dose intramuscular methotrexate
of 50 mg/m². On 10 <sup>th </sup> day patient was admitted with lethargy,
irritability, vomiting, hematemesis, diarrhea, oral mucositis and skin rash.
Laboratory findings revealed severe bone marrow suppression. Supportive
treatment together with antibacterial/ antifungal drugs and granulocyte colony
stimulating factors were administered. On the 3 <sup>rd </sup>day of treatment,
mucositis and oral intake began to improve. After 1 week complete blood count
was normal. Methotrexate may have mortal clinical consequences even with very
low doses. Therefore, a careful patient history for patient selection and
closer clinical follow-up are essential.  </span> </p> <p> </p>}, number={3}, publisher={Prusa Medical Publishing}